Long-Term Human Papillomavirus Vaccination Effectiveness and Immunity in Rwandan Women Living with and without Human Immunodeficiency Virus

Principal investigator: None
Check PI profile

Investigators

Gad Murenzi, Kathryn Anastos, Léon Mutesa, Adebola Adedimeji, Marcel Yotebieng, Gallican Kubwimana, Athanase Munyaneza, Fabienne Shumbusho, Philip Castle, Julia Gage, Brad Aouizerat, Robert Burk, Jose Jeronimo, Amanda Pierz, Natasha Hansen,

Study information

  • Research Area: Low and Middle income countries especially Rwanda and DRC
  • Research type: Rwandan Women Living with and without Human Immunodeficiency Virus
  • Start date: Sep 27, 2020
  • End date: Dec 30, 2023

Study aim of the objectives

1. To measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections by HPV6/11/16/18; and
2. To quantify, and examine the determinants of, long-term antibody (into young adulthood) responses to HPV vaccination

Study setting/Area (Location)

In Kigali, the study staff will work with five public clinics that participate in the International Epidemiology Databases to Evaluate AIDS (IeDEA) program and the WE-ACTx private clinic

Implementing institution

RMH

Department/Division

Research

Impact on Policy

The proposed study will provide the much-needed evidence regarding the long-term protection afforded by HPV vaccination in WLWH living in SSA, who are at the greatest risk of HPV-related cancers.

Related research

None

Login
Support